When high-potency OSD manufacturing goes global

The oral solid dose (OSD) market is undergoing a quiet but significant transformation. While conventional OSD remains the cornerstone of approximately 60% of the pharmaceutical market, the sector’s primary growth engine has shifted toward high-potency formulations, which are projected to expand at triple the rate of standard dose forms.

Being a global leader in developing and manufacturing OSD relies on the ability to meet this rising demand. With an expansive manufacturing network across Europe and into India, Recipharm has the strategic footprint necessary to match this market need and help bring critical therapeutics, including high-potency OSDs, to patients.

The need for specialised OSD facilities

High-potency drugs are increasingly the preferred format for treating complex conditions such as oncology. However, their manufacturing requirements differ significantly from standard OSDs. The heightened potency of the active ingredients poses a safety risk to handlers, meaning all production facilities must be adapted with specialised containment technologies and protocols.

The high-potency OSD market is expected to grow at 6-7% over the next few years, a rate triple that of the normal OSD market. As this surge continues, pharma companies will increasingly look to contract development and manufacturing organisations (CDMOs) for support, putting them to the test. 

At Recipharm, our site in Leganés, Spain, for one, is already operating with the advanced containment measures, such as plexiglass-protected equipment, needed to safely handle high-potency compounds.

Investing in facilities, investing in the future

Whether at our Leganés site or others across Europe and Asia, we are actively expanding our high-potency API capabilities to meet market demand, investing in pilot-scale and containment technologies and strengthening development infrastructure for complex formulations. 

These strategic investments ensure that as therapeutic molecules become more complex, the path from development to patient remains secure and efficient. 

Want to learn more about the benefits of a global OSD network? Read our full interview article in International Pharmaceutical Industry (IPI) here.